F Proulx1, J P Turgeon, G Delage, H Lior, L Lafleur, L Chicoine. 1. Departments of Pediatrics, Microbiology and Immunology, Hôpital Sainte-Justine, Université de Montréal, Montréal, Québec; and the National Centre for Enteric Bacteriology, Laboratory Centre for Disease Control, Ottawa, Ontario.
Abstract
OBJECTIVES: To compare neutralizing antibody titres against verotoxin (vt)-1 and vt-2 between children with uncomplicated hemorrhagic colitis (hc) and those with classic hemolytic uremic syndrome (hus). vt antibody titres were also compared in children with hc who received trimethoprim-sulfamethoxazole with those who did not. DESIGN: Prospective study. SETTING: Tertiary pediatric hospital. POPULATION STUDIED: Children with hc (n=41) or classic hus (n=12). INTERVENTIONS: Serum antibodies against vt-1 and vt-2 were determined by quantitative neutralization. MAIN RESULTS: Antibodies were detected in 40% (21 of 53) of serum samples for vt-1 and in 100% (53 of 53) of samples for vt-2. A positive immune response, defined as a fourfold increase in vt antibody titres or as a single titre of 1/64 or greater, was found in 0% (0 of 12) of patients with hus compared with 7% (three of 41) of those with hc for vt-1 (P=0.4); and in 17% (two of 12) of patients with hus compared with 22% (nine of 41) of those with hc for vt-2 (P=0.3). The rate of seroconversion against either vt-1 or vt-2 was comparable in treated and untreated patients with uncomplicated hc. CONCLUSIONS: There was no evidence that neutralizing antibody levels against vt-1 or vt-2 in classic hus or after antibiotic therapy are substantially different from those in patients with uncomplicated hc.
OBJECTIVES: To compare neutralizing antibody titres against verotoxin (vt)-1 and vt-2 between children with uncomplicated hemorrhagic colitis (hc) and those with classic hemolytic uremic syndrome (hus). vt antibody titres were also compared in children with hc who received trimethoprim-sulfamethoxazole with those who did not. DESIGN: Prospective study. SETTING: Tertiary pediatric hospital. POPULATION STUDIED: Children with hc (n=41) or classic hus (n=12). INTERVENTIONS: Serum antibodies against vt-1 and vt-2 were determined by quantitative neutralization. MAIN RESULTS: Antibodies were detected in 40% (21 of 53) of serum samples for vt-1 and in 100% (53 of 53) of samples for vt-2. A positive immune response, defined as a fourfold increase in vt antibody titres or as a single titre of 1/64 or greater, was found in 0% (0 of 12) of patients with hus compared with 7% (three of 41) of those with hc for vt-1 (P=0.4); and in 17% (two of 12) of patients with hus compared with 22% (nine of 41) of those with hc for vt-2 (P=0.3). The rate of seroconversion against either vt-1 or vt-2 was comparable in treated and untreated patients with uncomplicated hc. CONCLUSIONS: There was no evidence that neutralizing antibody levels against vt-1 or vt-2 in classic hus or after antibiotic therapy are substantially different from those in patients with uncomplicated hc.